Brigatinib 90mg
| Product Overview | |
| Generic Name | Brigatinib 90mg |
| Brand Name(s) | ALUNBRIG® |
| Form | 28 Film-coated tablets; oral use |
| Strength | 30 mg; 90 mg; 180 mg |
| Therapeutic Class | Antineoplastic agent; protein kinase inhibitor (ALK inhibitor) |
| ATC Code | L01ED04 |
| Manufacturing & Regulatory | |
| Manufacturer | Takeda Pharma |
| Country | Ireland |
| GMP Compliance | WHO-GMP/EU-GMP, EU/FDA-approved marketing authorisation |
| COFEPRIS | 193300EL870119 |
| Free Sale Certificate | only from the marketing authorisation holder or authorised country distributor |
| Logistics & Export | |
| MOQ | 10 Units |
| Shelf Life | 3 years / 36 months |
| Storage | ambient storage, 15–30°C or below 25°C |
| Incoterms | EXW |
| Lead Time | 7 - 10 Business Days |
| Documentation | |
| Certificate of Analysis (COA) | available from manufacturer/authorised distributor for institutional or regulatory transactions |
| CTD Summary | Full CTD is proprietary |
Description
An oral ALK inhibitor indicated for adult patients with ALK-positive advanced or metastatic non-small cell lung cancer
